Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.71 |
| ▸ | KDR | P35968 | 18/20 | 0.71 |
| ▸ | RET | P07949 | 2/20 | 0.61 |
| ▸ | KIF5B | P33176 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.56 |
| ▸ | FLT4 | P35916 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496725 | 0.93 | KDR (0.62) | EGFRKDRRETKIF5BBRAF | |
| SCHEMBL5496174 | 0.91 | EGFR (0.69) | EGFRKDRRETKIF5BBRAF | |
| SCHEMBL4418947 | 0.89 | EGFR (0.60) | EGFRKDRBRAFFGFR1 | |
| SCHEMBL5496194 | 0.85 | KDR (0.67) | EGFRKDRRETKIF5BFGFR1 | |
| SCHEMBL4422030 | 0.84 | EGFR (0.57) | EGFRKDRBRAF | |
| SCHEMBL5494771 | 0.84 | EGFR (0.53) | EGFRKDRBRAF | |
| SCHEMBL5498285 | 0.83 | BRAF (0.70) | EGFRKDRRETKIF5BBRAF | |
| SCHEMBL4689817 | 0.82 | SRC (0.64) | EGFRKDRRETKIF5BBRAF | |
| SCHEMBL4690799 | 0.82 | SRC (0.64) | EGFRKDRRETKIF5BBRAF | |
| SCHEMBL4421074 | 0.80 | KDR (0.57) | EGFRKDRRETKIF5BBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | claimed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |